All In Biotech

Drug Trial Radar · NCT05097287

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,339 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,339

Actual

Start

Dec 16, 2021

Primary completion

Mar 16, 2027

Study completion Jun 8, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.

Conditions

  • Asthma

Interventions

  • DupilumabDrug

    solution for injection subcutaneous

  • PlaceboDrug

    solution for injection subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO populationTime frame: Week 8 to Week 52

Locations

249 sites in 23 countries. Site status is shown where the registry gives one.

  • Cullman Research Center- Site Number : 8400001

    Cullman, Alabama

  • Shoals Primary Care - Sheffield- Site Number : 8400015

    Sheffield, Alabama

  • Chandler Clinical Research Trials- Site Number : 8400147

    Chandler, Arizona

  • Pulmonary Associates - Deer Valley Office- Site Number : 8400155

    Phoenix, Arizona

  • Medical Advancement Center of Arizona (MACOA)- Site Number : 8400130

    Phoenix, Arizona

  • Del Sol Research Management - Tucson- Site Number : 8400017

    Tucson, Arizona

  • Kern Allergy and Medical Research- Site Number : 8400037

    Bakersfield, California

  • Vitality Clinical Research- Site Number : 8400142

    Beverly Hills, California

  • Ascada Research - Fullerton- Site Number : 8400076

    Fullerton, California

  • Allergy and Asthma Specialists Medical Group- Site Number : 8400162

    Huntington Beach, California

  • Newport Native MD- Site Number : 8400054

    Newport Beach, California

  • Prospective Research Innovations- Site Number : 8400131

    Rancho Cucamonga, California

  • Mercy Medical Group - Midtown- Site Number : 8400164

    Sacramento, California

  • Integrated Research of Inland- Site Number : 8400156

    Upland, California

  • Allianz Research Institute- Site Number : 8400018

    Westminster, California

  • Woodland Clinic - Woodland- Site Number : 8400171

    Woodland, California

  • Central Florida Pulmonary Group - Altamonte Springs- Site Number : 8400035

    Altamonte Springs, Florida

  • Florida Center for Allergy & Asthma Research- Site Number : 8400032

    Aventura, Florida

  • Beautiful Minds Clinical Research Center- Site Number : 8400141

    Cutler Bay, Florida

  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400023

    DeBary, Florida

  • Florida Lung, Asthma and Sleep Specialists (FLASS) - Polynesian- Site Number : 8400098

    Kissimmee, Florida

  • Ivetmar Medical Group- Site Number : 8400063

    Miami, Florida

  • My Preferred Research- Site Number : 8400073

    Miami, Florida

  • Research Institute of South Florida- Site Number : 8400079

    Miami, Florida

  • Floridian Clinical Research - Miami Lakes- Site Number : 8400091

    Miami Lakes, Florida

  • Heuer M.D. Research- Site Number : 8400024

    Orlando, Florida

  • JSV Clinical Research- Site Number : 8400150

    Tampa, Florida

  • Appalachian Clinical Research- Site Number : 8400129

    Adairsville, Georgia

  • Alpha Clinical Research Group - Dunwoody- Site Number : 8400116

    Dunwoody, Georgia

  • Aeroallergy Research Laboratory- Site Number : 8400114

    Savannah, Georgia

  • Rush University Medical Center- Site Number : 8400146

    Chicago, Illinois

  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400138

    Skokie, Illinois

  • Family Allergy & Asthma - Louisville - Goss Avenue- Site Number : 8400160

    Louisville, Kentucky

  • Allergy and Asthma Specialist- Site Number : 8400007

    Owensboro, Kentucky

  • Avant Research Associates - Crowley- Site Number : 8400117

    Crowley, Louisiana

  • Investigational Site Number : 3560016

    Houma, Louisiana

  • Tandem Clinical Research - Metairie- Site Number : 8400163

    Metairie, Louisiana

  • Javara Privia Mid-Atlantic - Annapolis- Site Number : 8400087

    Annapolis, Maryland

  • Urgent Care Clinical Trials and KUR Research- Site Number : 8400169

    Columbia, Maryland

  • Chesapeake Clinical Research - White Marsh- Site Number : 8400119

    White Marsh, Maryland

Showing 40 of 249 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.